Axonics Modulation Technologies
Axonics Modulation Technologies is a medical device company that has developed a novel and potentially best-in-class sacral neuromodulation (SNM) system for the treatment of overactive bladder (OAB) and fecal incontinence. It will be the smallest, fully implantable and first rechargeable SNM device. It is expected to work in the body for up to 15 years. Axonics has CE Mark and is currently engaged in a US pivotal trial for the treatment of OAB.
Gilde has invested in Axonics out of Gilde Healthcare IV.
Axonics is now publicly listed on the NASDAQ under the ticker symbol AXNX.